Ventricular septal defect ACC/AHA guidelines: Difference between revisions
No edit summary |
No edit summary |
||
Line 9: | Line 9: | ||
'''Ventricular septal defect ACC/AHA guidelines ''' <ref name="pmid19038677">{{cite journal| author=Warnes CA, Williams RG, Bashore TM, Child JS, Connolly HM, Dearani JA et al.| title=ACC/AHA 2008 guidelines for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the Management of Adults With Congenital Heart Disease). Developed in Collaboration With the American Society of Echocardiography, Heart Rhythm Society, International Society for Adult Congenital Heart Disease, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. | journal=J Am Coll Cardiol | year= 2008 | volume= 52 | issue= 23 | pages= e1-121 | pmid=19038677 | doi=10.1016/j.jacc.2008.10.001 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19038677 }} </ref> | '''Ventricular septal defect ACC/AHA guidelines ''' <ref name="pmid19038677">{{cite journal| author=Warnes CA, Williams RG, Bashore TM, Child JS, Connolly HM, Dearani JA et al.| title=ACC/AHA 2008 guidelines for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the Management of Adults With Congenital Heart Disease). Developed in Collaboration With the American Society of Echocardiography, Heart Rhythm Society, International Society for Adult Congenital Heart Disease, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. | journal=J Am Coll Cardiol | year= 2008 | volume= 52 | issue= 23 | pages= e1-121 | pmid=19038677 | doi=10.1016/j.jacc.2008.10.001 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19038677 }} </ref> | ||
Line 18: | Line 19: | ||
The American College of Cardiology/American Heart Association (ACC/AHA) classification of the recommendations for patient evaluation and treatment (classes I-III) | The American College of Cardiology/American Heart Association (ACC/AHA) classification of the recommendations for patient evaluation and treatment (classes I-III) | ||
Clinical Features and Evaluation of the Unoperated Patient | Clinical Features and Evaluation of the Unoperated Patient | ||
Line 27: | Line 30: | ||
Class I | Class I | ||
*Cardiac catheterization to assess the operability of adults with ventricular septal defect (VSD) and pulmonary arterial hypertension (PAH) should be performed in an adult congenital heart disease (ACHD) regional center in collaboration with experts. (Level of Evidence: C) | *Cardiac catheterization to assess the operability of adults with ventricular septal defect (VSD) and pulmonary arterial hypertension (PAH) should be performed in an adult congenital heart disease (ACHD) regional center in collaboration with experts. (Level of Evidence: C) | ||
Line 32: | Line 36: | ||
Class IIa | Class IIa | ||
*Cardiac catheterization can be useful for adults with VSD in whom noninvasive data are inconclusive and further information is needed for management. Data to be obtained include the following: | *Cardiac catheterization can be useful for adults with VSD in whom noninvasive data are inconclusive and further information is needed for management. Data to be obtained include the following: | ||
*Quantification of shunting. (Level of Evidence: B) | *Quantification of shunting. (Level of Evidence: B) | ||
Line 41: | Line 47: | ||
**Performance of coronary arteriography is indicated in patients at risk for coronary artery disease. (Level of Evidence: C) | **Performance of coronary arteriography is indicated in patients at risk for coronary artery disease. (Level of Evidence: C) | ||
**VSD anatomy, especially if device closure is contemplated. (Level of Evidence: C) | **VSD anatomy, especially if device closure is contemplated. (Level of Evidence: C) | ||
Management Strategies | Management Strategies | ||
Recommendation for Medical Therapy | Recommendation for Medical Therapy | ||
Line 50: | Line 58: | ||
*Pulmonary vasodilator therapy may be considered for adults with VSDs with progressive/severe pulmonary vascular disease (refer to the National Guideline Clearinghouse [NGC] summary of the ACC/AHA guideline, Pulmonary Hypertension/Eisenmenger Physiology). (Level of Evidence: B) | *Pulmonary vasodilator therapy may be considered for adults with VSDs with progressive/severe pulmonary vascular disease (refer to the National Guideline Clearinghouse [NGC] summary of the ACC/AHA guideline, Pulmonary Hypertension/Eisenmenger Physiology). (Level of Evidence: B) | ||
Recommendations for Surgical Ventricular Septal Defect Closure | Recommendations for Surgical Ventricular Septal Defect Closure | ||
Line 55: | Line 65: | ||
Class I | Class I | ||
*Surgeons with training and expertise in congenital heart disease (CHD) should perform VSD closure operations. (Level of Evidence: C) | *Surgeons with training and expertise in congenital heart disease (CHD) should perform VSD closure operations. (Level of Evidence: C) | ||
**Closure of a VSD is indicated when there is a Qp/Qs (pulmonary–to–systemic blood flow ratio) of 2.0 or more and clinical evidence of left ventricular (LV) volume overload. (Level of Evidence: B) | **Closure of a VSD is indicated when there is a Qp/Qs (pulmonary–to–systemic blood flow ratio) of 2.0 or more and clinical evidence of left ventricular (LV) volume overload. (Level of Evidence: B) | ||
**Closure of a VSD is indicated when the patient has a history of infective endocarditis (IE). (Level of Evidence: C) | **Closure of a VSD is indicated when the patient has a history of infective endocarditis (IE). (Level of Evidence: C) | ||
Class IIa | Class IIa | ||
*Closure of a VSD is reasonable when net left-to-right shunting is present at a pulmonary blood flow/systemic blood flow (Qp/Qs) greater than 1.5 with pulmonary artery pressure less than two thirds of systemic pressure and PVR less than two thirds of systemic vascular resistance. (Level of Evidence: B) | *Closure of a VSD is reasonable when net left-to-right shunting is present at a pulmonary blood flow/systemic blood flow (Qp/Qs) greater than 1.5 with pulmonary artery pressure less than two thirds of systemic pressure and PVR less than two thirds of systemic vascular resistance. (Level of Evidence: B) | ||
**Closure of a VSD is reasonable when net left-to-right shunting is present at a Qp/Qs greater than 1.5 in the presence of LV systolic or diastolic failure. (Level of Evidence: B) | **Closure of a VSD is reasonable when net left-to-right shunting is present at a Qp/Qs greater than 1.5 in the presence of LV systolic or diastolic failure. (Level of Evidence: B) | ||
Line 70: | Line 85: | ||
*VSD closure is not recommended in patients with severe irreversible PAH. (Level of Evidence: B) | *VSD closure is not recommended in patients with severe irreversible PAH. (Level of Evidence: B) | ||
Recommendation for Interventional Catheterization | Recommendation for Interventional Catheterization | ||
Line 75: | Line 92: | ||
Class IIb | Class IIb | ||
*Device closure of a muscular VSD may be considered, especially if the VSD is remote from the tricuspid valve and the aorta, if the VSD is associated with severe left-sided heart chamber enlargement, or if there is PAH. (Level of Evidence: C) | *Device closure of a muscular VSD may be considered, especially if the VSD is remote from the tricuspid valve and the aorta, if the VSD is associated with severe left-sided heart chamber enlargement, or if there is PAH. (Level of Evidence: C) | ||
Key Issues to Evaluate and Follow-Up | Key Issues to Evaluate and Follow-Up | ||
Recommendations for Surgical and Catheter Intervention Follow-Up | Recommendations for Surgical and Catheter Intervention Follow-Up | ||
Class I | |||
*Adults with VSD with residual heart failure, shunts, PAH, aortic regurgitation (AR), or right ventricular outflow tract (RVOT) or left ventricular outflow tract (LVOT) obstruction should be seen at least annually at an ACHD regional center. (Level of Evidence: C) | *Adults with VSD with residual heart failure, shunts, PAH, aortic regurgitation (AR), or right ventricular outflow tract (RVOT) or left ventricular outflow tract (LVOT) obstruction should be seen at least annually at an ACHD regional center. (Level of Evidence: C) | ||
**Adults with a small residual VSD and no other lesions should be seen every 3 to 5 years at an ACHD regional center. (Level of Evidence: C) | **Adults with a small residual VSD and no other lesions should be seen every 3 to 5 years at an ACHD regional center. (Level of Evidence: C) | ||
**Adults with device closure of a VSD should be followed up every 1 to 2 years at an ACHD center depending on the location of the VSD and other factors. (Level of Evidence: C) | **Adults with device closure of a VSD should be followed up every 1 to 2 years at an ACHD center depending on the location of the VSD and other factors. (Level of Evidence: C) | ||
Recommendation for Reproduction | Recommendation for Reproduction | ||
Line 94: | Line 117: | ||
Class III | Class III | ||
*Pregnancy in patients with VSD and severe PAH (Eisenmenger syndrome) is not recommended owing to excessive maternal and fetal mortality and should be strongly discouraged. (Level of Evidence: A)}} | *Pregnancy in patients with VSD and severe PAH (Eisenmenger syndrome) is not recommended owing to excessive maternal and fetal mortality and should be strongly discouraged. (Level of Evidence: A)}} | ||
==References== | ==References== |
Revision as of 14:53, 11 July 2011
Ventricular septal defect Microchapters | |
Differentiating Ventricular Septal Defect from other Diseases | |
---|---|
Diagnosis | |
ACC/AHA Guidelines for Surgical and Catheter Intervention Follow-Up | |
Case Studies | |
Ventricular septal defect ACC/AHA guidelines On the Web | |
American Roentgen Ray Society Images of Ventricular septal defect ACC/AHA guidelines | |
Risk calculators and risk factors for Ventricular septal defect ACC/AHA guidelines | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]and Leida Perez, M.D.
Associate Editor-In-Chief: Keri Shafer, M.D. [2],Atif Mohammad, M.D., Priyamvada Singh, MBBS
Ventricular septal defect ACC/AHA guidelines [1]
Major Recommendations (DONOT EDIT)
“ |
Clinical Features and Evaluation of the Unoperated Patient
Recommendations for Cardiac Catheterization
Recommendations for Surgical Ventricular Septal Defect Closure
Recommendation for Interventional Catheterization
|
” |
References
- ↑ Warnes CA, Williams RG, Bashore TM, Child JS, Connolly HM, Dearani JA; et al. (2008). "ACC/AHA 2008 guidelines for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the Management of Adults With Congenital Heart Disease). Developed in Collaboration With the American Society of Echocardiography, Heart Rhythm Society, International Society for Adult Congenital Heart Disease, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons". J Am Coll Cardiol. 52 (23): e1–121. doi:10.1016/j.jacc.2008.10.001. PMID 19038677.
de:Herzfehler lv:Iedzimtās sirds slimības nn:Medfødd hjartefeil sr:Урођене срчане мане uk:Вроджені вади серця wa:Maladeye des bleus påpåds